Refine by
In Vivo Model Articles & Analysis
38 news found
Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. ...
I feel pleased to share our work on one synthesized PDC that has shown promising in vitro results and is currently undergoing in vivo evaluation in mice models of pulmonary fibrosis," stated Dr. Kelly Bugatti. ...
These services encompass cell-level screening, identification of cell lines and models, genotyping services for rats and mice, PET-CT services, and flow cytometry services. ...
In light of the growing needs of customers for novel antiviral and antibacterial compounds to treat infectious diseases, Creative Diagnostics is leveraging its expertise to perform in vitro testing for compounds, thus, estimating their potential efficacies using in vivo models. If you have questions regarding the Microneutralization Assay Service or other In ...
This formulation (Bupigel) prolonged bupivacaine release from the formulation in dissolution-like studies in vitro and analgesia in vivo in mouse, rat, and pig models. In this study we assessed Bupigel neurotoxicity on rabbit sciatic nerve using histopathology and electrophysiologic testing. ...
Highlights: ES019 phagocytosis activity is corrected with PD-L1 level on tumor cells ES019 leads to better phagocytosis capability of tumor cells by M2-like than M1-like macrophage ES019 activates T cells without induction of phagocytosis of T cells ES019 shows favorable PK in mouse model ES019 demonstrates single agent anti-tumor efficacy in animal ...
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s Identified two lead cannabinoid analog compounds for in vivo studies NSERC grant funding supports InMed’s collaborative research projects with Dr. ...
According to the classification of drugs and the characteristics of pharmacological effects, the efficacy and mechanism of drugs are reflected through appropriate in vitro and in vivo models, providing a basis for new drug development and supporting clinical research. ...
Confronting the growing demands for new antiviral and antimicrobial compounds as treatments for infectious diseases, Creative Diagnostics spares no effort to test these compounds in vitro to determine potential efficacy within in vivo models. If you need more information regarding the Fluorometric Neuraminidase Assay Service or have any questions related to the ...
In the context of solid tumors, preclinical data presented at the 2021 American Association for Cancer Research annual meeting demonstrate that IO-202 enhances dendritic cell function and T cell activation in vitro and inhibits tumor growth in an immune competent model in vivo. IO-202 has two ongoing clinical studies in the U.S.: Its first Phase 1 trial is ...
The investigational product must be established to possess antiviral activity at concentrations achievable in vivo without causing toxic effects on cells. Furthermore, in cell culture models, the apparent antiviral activity of the investigational product may be the result of host cell death following exposure to the product. ...
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In vivo studies of an AML murine model ...
SER-155 is designed using microbiome biomarker data from human clinical data, human cell-based assays, and in vivo disease models, with the aim to decrease infection and translocation of antibiotic-resistant bacteria in the gastrointestinal tract and modulate host immune responses to decrease GvHD. ...
Across a variety of preclinical models, SER-155 appears to work by reducing gastrointestinal (GI) inflammation, fortifying the protective GI lining, and promoting immune cell balance in the gut. ...
The design incorporates microbiome biomarker data from human clinical data and nonclinical human cell-based assays and in vivo disease models. The SER-155 composition aims to decrease the colonization and translocation of antibiotic-resistant bacteria in the gastrointestinal tract to decrease the incidence of bloodstream infections and additionally to modulate ...
In the context of solid tumors, preclinical studies showed that IO-202 enhances dendritic cell function and T cell activation in vitro and inhibits tumor growth in an immune competent model in vivo. IO-202 has two ongoing clinical studies: Its first Phase 1 trial is currently enrolling patients with acute myeloid leukemia (AML) or chronic myelomonocytic leukemia ...
Exclusively in-licensed from UofL, compounds from this discovery engine have been shown to inhibit a broad range of RAS mutations and are active against the growth of multiple in vivo tumor models. Qualigen is evaluating promising compounds generated from this partnership in various RAS-driven advanced solid tumors such as pancreatic, colorectal and lung cancers. ...
Stephen Neidle Session Title: Structural and Chemical Biology Session Date and Time: Tuesday Apr 12, 2022 9:00 AM - 12:30 PM CDT Abstract Number: 4069 Title: “The potent quadruplex-binding compound SOP1812 shows anti-tumor activity in patient-derived in vivo models of pancreatic cancer” Lead Author: ...
INOVOTION’s high-value preclinical oncology assay quickly identifies your most effective anticancer drug candidates. Our unique technology guarantees fast, reliable, sensitive, and cost-effective results. And it will help you meet the 3Rs guidelines. Learn more and download one of our webinars! Take a step into the future of drug discovery!!! Let’s discover together how ...
Through this mechanism, QN-302 has demonstrated anti-tumor activity in multiple tumor types, including in-vivo PDAC models, without toxicity at proposed therapeutic doses. Further, studies suggest encouraging anti-tumor activity against gemcitabine-resistant tumors. ...